Moderna Settles Global Litigation with Arbutus and Genevant Sciences for $950 Million

Moderna has reached an agreement to pay $950 million to resolve all legal disputes globally with Arbutus Biopharma and Genevant Sciences. Bloomberg posted on X that the settlement covers existing and future vaccines, ensuring that no future royalties will be owed by Moderna. This resolution marks a significant step for Moderna in clearing legal hurdles related to its vaccine development. The agreement aims to eliminate ongoing litigation, allowing Moderna to focus on its vaccine production and distribution efforts without the burden of potential royalty payments. The settlement underscores the importance of resolving intellectual property disputes in the pharmaceutical industry, particularly as companies continue to innovate and expand their vaccine portfolios.